These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 1719865)

  • 1. Tachykinins and related peptides in the substantia nigra and neostriatum.
    Hökfelt T; Reid M; Herrera-Marschitz M; Ungerstedt U; Terenius L; Håkanson R; Feng DM; Folkers K
    Ann N Y Acad Sci; 1991; 632():192-7. PubMed ID: 1719865
    [No Abstract]   [Full Text] [Related]  

  • 2. Differential effects of tachykinins injected intranigrally on striatal dopamine metabolism.
    Tan DP; Tsou K
    J Neurochem; 1988 Nov; 51(5):1333-7. PubMed ID: 2459306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of substance P in the nigrostriatal system.
    Borison RL; Klawans HL; Diamond BI
    Int J Neurol; 1980; 14(2-4):189-94. PubMed ID: 6194132
    [No Abstract]   [Full Text] [Related]  

  • 4. Injection of tachykinins and selective neurokinin receptor ligands into the substantia nigra reticulata increases striatal dopamine and 5-hydroxytryptamine metabolism.
    Humpel C; Saria A; Regoli D
    Eur J Pharmacol; 1991 Mar; 195(1):107-14. PubMed ID: 1712305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pretreatment with fragments of substance-P or with cholecystokinin differentially affects recovery from sub-total nigrostriatal 6-hydroxydopamine lesion.
    Nikolaus S; Huston JP; Schwarting RK
    Neural Plast; 1999; 6(4):77-89. PubMed ID: 10714262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of the immunoneutralization of substance P in the cat substantia nigra on the release of dopamine from dendrites and terminals of dopaminergic neurons.
    Cheramy A; Michelot R; Leviel V; Nieoullon A; Glowinski J; Kerdelhue B
    Brain Res; 1978 Oct; 155(2):404-8. PubMed ID: 688024
    [No Abstract]   [Full Text] [Related]  

  • 7. The selective NK3 receptor agonist senktide excites a subpopulation of dopamine-sensitive neurones in the rat substantia nigra pars compacta in vitro.
    Keegan KD; Woodruff GN; Pinnock RD
    Br J Pharmacol; 1992 Jan; 105(1):3-5. PubMed ID: 1375857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of striato-nigral substance P in the regulation of the activity of the nigro-striatal dopaminergic neurons.
    Glowinski J; Michelot R; Chéramy A
    Adv Biochem Psychopharmacol; 1980; 22():51-62. PubMed ID: 6156583
    [No Abstract]   [Full Text] [Related]  

  • 9. Recovery from unilateral 6-hydroxydopamine lesion of substantia nigra promoted by the neurotachykinin substance P 1-11.
    Mattioli R; Schwarting RK; Huston JP
    Neuroscience; 1992; 48(3):595-605. PubMed ID: 1376454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Response of striatonigral substance P systems to a dopamine receptor agonist and antagonist.
    Hanson G; Alphs L; Pradhan S; Lovenberg W
    Neuropharmacology; 1981 Jun; 20(6):541-8. PubMed ID: 6165922
    [No Abstract]   [Full Text] [Related]  

  • 11. Contribution to the study of nigrostriatal dopaminergic neuron activity using electrochemical detection of dopamine release in the striatum of freely moving animals.
    Nieoullon A; Forni C; el Ganouni S
    Ann N Y Acad Sci; 1986; 473():126-40. PubMed ID: 3099623
    [No Abstract]   [Full Text] [Related]  

  • 12. Effects of the unilateral nigral modulation of substance P transmission on the activity of the two nigro-striatal dopaminergic pathways.
    Michelot R; Leviel V; Giorguieff-Chesselet MF; Chéramy A; Glowinski J
    Life Sci; 1979 Feb; 24(8):715-23. PubMed ID: 86931
    [No Abstract]   [Full Text] [Related]  

  • 13. Substance P modulates cocaine-evoked dopamine overflow in the striatum of the rat brain.
    Kraft M; Noailles P; Angulo JA
    Ann N Y Acad Sci; 2001 Jun; 937():121-31. PubMed ID: 11458533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of section of the strionigral fibers on dopamine turnover in the forebrain of the rat.
    Bedard P; Larochelle L
    Exp Neurol; 1973 Nov; 41(2):314-22. PubMed ID: 4746196
    [No Abstract]   [Full Text] [Related]  

  • 15. Dopaminergic regulation of tachykinin metabolism in the striatonigral pathway.
    Li SJ; Sivam SP; McGinty JF; Huang YS; Hong JS
    J Pharmacol Exp Ther; 1987 Nov; 243(2):792-8. PubMed ID: 2445959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of the mesostriatal dopamine pathway.
    Strange PG
    Trends Neurosci; 1990 Mar; 13(3):93-5. PubMed ID: 1691877
    [No Abstract]   [Full Text] [Related]  

  • 17. Intranigral substance P stimulation of striatal dopamine release is inhibited by spantide II: a new tachykinin antagonist without apparent neurotoxicity.
    Reid MS; Hökfelt T; Herrera-Marschitz M; Håkanson R; Feng DM; Folkers K; Goldstein M; Ungerstedt U
    Brain Res; 1990 Nov; 532(1-2):175-81. PubMed ID: 1704289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intranigral injection of dynorphin in combination with substance P on striatal dopamine metabolism in the rat.
    Tan DP; Tsou K
    Brain Res; 1988 Mar; 443(1-2):310-4. PubMed ID: 2451993
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Substance P antagonists in substantia nigra are anticonvulsant.
    Garant DS; Iadarola MJ; Gale K
    Brain Res; 1986 Sep; 382(2):372-8. PubMed ID: 2428445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does dopamine contribute to striatal damage caused by impaired mitochondrial function?
    Maragos WF; Jakel RJ; Chesnut MD; Geddes JW; Dwoskin LP
    Ann N Y Acad Sci; 1999; 893():345-9. PubMed ID: 10672263
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.